Document Detail


T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
MedLine Citation:
PMID:  16614234     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
T-cell/histiocyte-rich B-cell lymphoma (T/HRBCL) is an uncommon morphologic variant of diffuse large B-cell lymphoma (DLBCL). Pathologically, it is distinguished by <10% malignant B cells amid a majority population of reactive T lymphocytes and histiocytes. Diagnosis of this entity is occasionally difficult, as it may appear similar to other lymphoid diseases, such as nodular lymphocyte-predominant Hodgkin's lymphoma and classic Hodgkin's lymphoma. Accurate diagnosis therefore rests with careful immunohistochemical analysis of the tumor cells and the inflammatory microenvironment. Clinically, T/HRBCL occurs in younger patients, predominantly affects men, and involves the liver, spleen, and bone marrow with greater frequency than traditional DLBCL. Despite the unique clinical features and robust host inflammatory response, T/HRBCL follows a natural history similar to those of other DLBCLs and responds similarly to therapy. Recent gene expression analysis demonstrates that a productive relationship with the host immune response may extend beyond this small DLBCL variant to include as many as one third of all DLBCLs. At present, T/HRBCL should be treated similarly to other stage-matched DLBCLs, though future therapies will likely be targeted at the relationship of the tumor cells with their inflammatory microenvironment.
Authors:
Jeremy S Abramson
Related Documents :
12587044 - Who is who and what was real?
23219714 - Delayed myelosuppression with acute exposure to hexahydro-1,3,5-trinitro-1,3,5-triazine...
19305144 - Upregulation of the cdc25a phosphatase down-stream of the npm/alk oncogene participates...
17149964 - Pediatric cd56+ anaplastic large cell lymphoma: a review of the literature.
8322704 - Disseminated intravascular coagulation in a patient with acute myeloid leukemia. ultras...
9130644 - Cytotoxicity and weak cd40 ligand expression of cd8+ type 2 cytotoxic t cells restricts...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The oncologist     Volume:  11     ISSN:  1083-7159     ISO Abbreviation:  Oncologist     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-14     Completed Date:  2006-09-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  384-92     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. jeremy_abramson@dfci.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Humans
Lymphoma, B-Cell / diagnosis*,  pathology,  therapy*
Lymphoma, Large B-Cell, Diffuse / diagnosis*,  pathology,  therapy*
Lymphoma, T-Cell / diagnosis*,  pathology,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Burkitt's lymphoma: clinicopathologic features and differential diagnosis.
Next Document:  The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection.